Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spina…
Drug Manufacturers - General
US, Cambridge [HQ]
Ratios
15 Sheets · Starting from 2023Margins, Growth Rates In %
| Ratio | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||||||||
| Gross Margin | 91.27 | 91.51 | 90.75 | 90.11 | 87.63 | 87.93 | 88.48 | 87.08 | 86.72 | 86.50 | 86.40 | 86.57 | 80.79 | 77.61 | 74.24 | |
| Profit Margin | 22.16 | 21.31 | 24.45 | 25.02 | 26.87 | 30.25 | 32.95 | 32.34 | 20.69 | 32.93 | 40.96 | 29.76 | 14.17 | 29.95 | 11.81 | |
| Operating Margin | 29.59 | 26.48 | 34.16 | 33.64 | 36.29 | 40.94 | 45.44 | 44.99 | 43.54 | 43.77 | 48.98 | 33.84 | 25.87 | 22.81 | 13.18 | |
|
EPS Growth
|
26.22 | 18.10 | 27.89 | 13.95 | 35.52 | 58.02 | 23.83 | 10.27 | -29.60 | 81.07 | 45.56 | -21.00 | -58.01 | 100.86 | -61.76 | |
| EPS USD | 337.00 | 398.00 | 509.00 | 580.00 | 786.00 | 1,242.00 | 1,538.00 | 1,696.00 | 1,194.00 | 2,162.00 | 3,147.00 | 2,486.00 | 1,044.00 | 2,097.00 | 802.00 | |
| Return on Assets (ROA) | 11.34 | 12.42 | 13.64 | 13.62 | 15.70 | 20.50 | 18.19 | 16.19 | 10.73 | 17.52 | 21.62 | 16.25 | 6.52 | 12.41 | 4.33 | |
| Return on Equity (ROE) | 15.59 | 18.63 | 19.21 | 19.82 | 21.60 | 27.14 | 37.84 | 30.53 | 20.15 | 34.00 | 44.14 | 37.44 | 14.20 | 22.76 | 7.85 | |
| Return on Invested Capital (ROIC) | 12.97 | 13.82 | 17.04 | 17.09 | 20.68 | 26.11 | 23.26 | 20.69 | 15.01 | 23.54 | 29.93 | 19.66 | 14.84 | 9.51 | 5.25 | |
| Solvency | ||||||||||||||||
| Equity Ratio | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Debt/Assets | 12.86 | 14.87 | 11.76 | 11.26 | 5.02 | 4.09 | 33.46 | 28.49 | 25.11 | 23.48 | 23.38 | 32.14 | 31.84 | 27.33 | 27.34 | |
| Debt/Equity | 17.68 | 22.30 | 16.56 | 16.38 | 6.91 | 5.41 | 69.62 | 53.74 | 47.14 | 45.56 | 47.74 | 74.03 | 69.38 | 50.13 | 49.58 | |
| Debt/EBITDA | 29.24 | 22.82 | 27.69 | 28.17 | -0.24 | -14.24 | 94.42 | 64.00 | 66.83 | 68.68 | 45.94 | 135.15 | 146.10 | 118.94 | 241.96 | |
|
Debt/Capitalization
|
15.02 | 18.24 | 14.20 | 14.08 | 6.47 | 5.13 | 41.04 | 34.95 | 32.04 | 31.30 | 32.31 | 42.54 | 40.96 | 33.39 | 33.15 | |
| Long-Term Debt/Capitalization | 14.79 | 16.50 | 14.17 | 8.98 | 6.43 | 5.11 | 41.03 | 34.94 | 32.02 | 31.30 | 26.75 | 42.28 | 37.60 | 33.07 | 32.69 | |
| Interest Debt per Share USD | 3.95 | 4.91 | 4.53 | 4.95 | 2.65 | 2.60 | 28.70 | 31.03 | 29.11 | 29.95 | 35.03 | 50.55 | 52.70 | 47.89 | 52.42 | |
| Debt Growth | -1.18 | 9.42 | -11.59 | 7.21 | -47.76 | -1.80 | 1,014.41 | -0.14 | -8.87 | 0.03 | 7.26 | 22.94 | -2.87 | -13.01 | 10.95 | |
| Liquidity | ||||||||||||||||
| Current Ratio | 346.96 | 241.92 | 325.94 | 195.75 | 181.14 | 210.51 | 259.93 | 261.69 | 233.75 | 231.88 | 172.33 | 184.04 | 182.79 | 299.17 | 199.73 | |
| Quick Ratio | 280.96 | 195.00 | 249.24 | 144.36 | 116.43 | 141.36 | 180.61 | 189.90 | 162.58 | 166.80 | 130.69 | 120.89 | 124.51 | 214.78 | 91.72 | |
| Cash Ratio | 81.39 | 72.33 | 56.36 | 34.43 | 34.27 | 54.28 | 50.74 | 69.72 | 46.73 | 37.16 | 59.91 | 35.57 | 52.61 | 104.48 | 30.57 | |
| Operating Cash Flow Ratio | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | - - | - - | - - | |
| Turnover | ||||||||||||||||
| Inventory Turnover | 129.99 | 138.47 | 142.82 | 121.93 | 130.16 | 145.65 | 138.84 | 147.63 | 180.57 | 195.32 | 243.15 | 168.93 | 156.10 | 169.47 | 100.24 | |
| Receivables Turnover | 587.57 | 561.49 | 863.60 | 803.16 | 840.87 | 750.77 | 877.25 | 794.17 | 686.84 | 686.90 | 764.58 | 702.51 | 708.77 | 476.19 | 468.36 | |
| Payables Turnover | 322.36 | 246.27 | 250.35 | 267.40 | 390.03 | 510.97 | 463.87 | 528.49 | 412.14 | 490.23 | 368.39 | 396.83 | 358.06 | 463.54 | 628.17 | |
|
Asset Turnover
|
51.19 | 58.28 | 55.79 | 54.46 | 58.43 | 67.78 | 55.19 | 50.05 | 51.89 | 53.20 | 52.79 | 54.61 | 45.99 | 41.43 | 36.64 | |
| Fixed Turnover | 267.39 | 287.30 | 321.29 | 316.63 | 395.97 | 549.55 | 492.04 | 457.62 | 385.68 | 373.57 | 391.31 | 349.68 | 289.62 | 274.77 | 263.71 | |
| Coverage | ||||||||||||||||
| Interest Coverage | 3,618.51 | 3,459.53 | 5,226.34 | 5,084.52 | 7,885.61 | 13,465.81 | 5,121.47 | 1,980.92 | 2,130.86 | 2,935.49 | 3,758.06 | 2,044.99 | 1,120.15 | 940.88 | 525.23 | |
| Asset Coverage | 500 | 400 | 600 | 600 | 900 | 1,300 | 100 | 200 | 200 | 300 | 300 | 200 | 200 | 200 | 200 | |
| Cash Flow Coverage (CFGR) | 97.72 | 134.99 | 162.37 | 164.79 | 393.52 | 502.76 | 56.94 | 69.39 | 76.64 | 104.23 | 111.17 | 53.46 | 47.87 | 20.63 | 21.08 | |
| EBITDA Coverage | 4,900 | 5,300 | 6,000 | 5,500 | 8,800 | 14,700 | 5,700 | 2,500 | 2,600 | 3,400 | 4,000 | 2,100 | 1,400 | 1,000 | 1,000 | |
| Dividend Coverage | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | 100 | 100 | 100 | 100 | 100 | 100 | 200 | 200 | 200 | 200 | 200 | 100 | 100 | 100 | 100 | |
| Market Prospects | ||||||||||||||||
| Dividend Yield | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Earnings Yield | 6.31 | 5.94 | 4.63 | 3.96 | 2.81 | 3.66 | 5.02 | 5.98 | 3.75 | 7.19 | 10.61 | 10.15 | 4.35 | 7.57 | 3.10 | |
|
Price/Earnings (P/E)
|
1,584.69 | 1,682.84 | 2,160.97 | 2,523.63 | 3,556.59 | 2,733.83 | 1,992.53 | 1,672.62 | 2,667.40 | 1,391.62 | 942.82 | 984.80 | 2,298.83 | 1,320.57 | 3,224.87 | |
| Price/Earnings Growth (PEG) | 60.44 | 92.97 | 77.48 | 180.92 | 100.14 | 47.12 | 83.61 | 162.82 | -90.12 | 17.17 | 20.69 | -46.89 | -39.63 | 13.09 | -52.22 | |
|
Price/Book (P/B)
|
247.10 | 313.48 | 415.06 | 500.12 | 768.32 | 741.92 | 753.87 | 510.64 | 537.60 | 473.15 | 416.21 | 368.68 | 326.40 | 300.53 | 253.01 | |
| Price/Tangible Book (P/TB) | 247.10 | 313.48 | 415.06 | 500.12 | 768.32 | 741.92 | 753.87 | 510.64 | 537.60 | 473.15 | 416.21 | 368.68 | 326.40 | 300.53 | 253.01 | |
| Price/Sales (P/S) | 351.21 | 358.69 | 528.37 | 631.33 | 955.48 | 826.85 | 656.60 | 540.96 | 551.80 | 458.33 | 386.14 | 293.04 | 325.74 | 395.51 | 380.70 | |
|
Price/Cash Flow (P/CF)
|
1,430.23 | 1,041.27 | 1,543.96 | 1,852.60 | 2,824.47 | 2,727.02 | 1,901.86 | 1,369.49 | 1,488.20 | 996.47 | 784.31 | 931.44 | 982.78 | 2,906.63 | 2,420.11 | |
| Price/Free CF (P/FCF) | 1,690.79 | 1,165.40 | 1,807.82 | 2,151.52 | -5,690.75 | 3,022.65 | 2,299.79 | 1,632.12 | 2,616.80 | 1,163.02 | 866.24 | 1,071.18 | 1,069.42 | 3,526.11 | 3,029.94 | |
| Price/Operating CF (P/OCF) | 1,430.23 | 1,041.27 | 1,543.96 | 1,852.60 | 2,824.47 | 2,727.02 | 1,901.86 | 1,369.49 | 1,488.20 | 996.47 | 784.31 | 931.44 | 982.78 | 2,906.63 | 2,420.11 |